Q2 2024 EPS Estimates for Danaher Co. (NYSE:DHR) Reduced by William Blair

Danaher Co. (NYSE:DHR) – Equities research analysts at William Blair lowered their Q2 2024 earnings per share estimates for Danaher in a report released on Wednesday, April 24th. William Blair analyst M. Larew now anticipates that the conglomerate will post earnings per share of $1.56 for the quarter, down from their prior estimate of $1.61. The consensus estimate for Danaher’s current full-year earnings is $7.62 per share. William Blair also issued estimates for Danaher’s Q3 2024 earnings at $1.73 EPS, Q4 2024 earnings at $2.45 EPS, Q1 2025 earnings at $2.29 EPS, Q2 2025 earnings at $1.86 EPS, Q3 2025 earnings at $1.98 EPS, Q4 2025 earnings at $2.77 EPS and FY2025 earnings at $8.90 EPS.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.48% and a net margin of 16.78%. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter last year, the business earned $2.36 earnings per share. Danaher’s revenue was down 2.6% on a year-over-year basis.

A number of other research analysts have also recently issued reports on the company. Raymond James lifted their target price on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Barclays lifted their target price on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday. Citigroup lifted their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday. Bank of America lifted their price target on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, TD Cowen lifted their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $270.00.

Danaher Stock Performance

Danaher stock opened at $250.41 on Thursday. Danaher has a 12-month low of $182.09 and a 12-month high of $259.00. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The business’s 50-day moving average price is $249.00 and its two-hundred day moving average price is $230.78. The stock has a market cap of $185.44 billion, a PE ratio of 42.44, a P/E/G ratio of 4.24 and a beta of 0.83.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a $0.27 dividend. The ex-dividend date is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s payout ratio is 18.31%.

Insider Buying and Selling at Danaher

In other Danaher news, Director Teri List sold 3,289 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Danaher news, Director Teri List sold 3,289 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,957 shares of company stock valued at $8,265,802. 11.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Danaher

Several hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP increased its holdings in shares of Danaher by 12.0% during the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after acquiring an additional 2,998,161 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Danaher by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after buying an additional 1,619,586 shares in the last quarter. Capital International Investors grew its holdings in Danaher by 9.1% during the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after buying an additional 1,334,781 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Danaher by 6.5% during the third quarter. Bank of New York Mellon Corp now owns 8,183,501 shares of the conglomerate’s stock worth $2,030,327,000 after buying an additional 502,868 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Danaher by 1.7% during the third quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock worth $2,009,789,000 after buying an additional 134,905 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.